U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Aggressive Variant Prostate Carcinoma

MedGen UID:
1774847
•Concept ID:
C5417704
•
Neoplastic Process
Synonyms: Aggressive Variant Prostate Cancer; Anaplastic Prostate Cancer; Anaplastic Prostate Carcinoma; Metastatic Aggressive Variant Prostate Cancer; Metastatic Aggressive Variant Prostate Carcinoma; Treatment-Related Anaplastic Prostate Cancer; Treatment-Related Anaplastic Prostate Carcinoma

Definition

A lethal form of advanced castration-resistant prostate carcinoma that emerges in the later stages of castration-resistant treatment. It is an adaptive response to androgen receptor pathway inhibition. The morphologic features vary, ranging from poorly differentiated carcinomas to mixed adenocarcinoma-small cell carcinomas to pure small cell carcinomas expressing neuroendocrine markers. Clinically, it manifests with rapidly progressive disease, visceral or lytic bone metastases and bulky tumor masses. Molecular studies have shown the loss of tumor suppressor genes TP53 and RB1. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVAggressive Variant Prostate Carcinoma

Professional guidelines

PubMed

Optimizing the diagnosis and management of ductal prostate cancer.
Ranasinghe W, Shapiro DD, Zhang M, Bathala T, Navone N, Thompson TC, Broom B, Aparicio A, Tu SM, Tang C, Davis JW, Pisters L, Chapin BF
Nat Rev Urol 2021 Jun;18(6):337-358. Epub 2021 Apr 6 doi: 10.1038/s41585-021-00447-3. PMID: 33824525
Clinical and molecular features of treatment-related neuroendocrine prostate cancer.
Akamatsu S, Inoue T, Ogawa O, Gleave ME
Int J Urol 2018 Apr;25(4):345-351. Epub 2018 Feb 3 doi: 10.1111/iju.13526. PMID: 29396873
The role of genetic markers in the management of prostate cancer.
Choudhury AD, Eeles R, Freedland SJ, Isaacs WB, Pomerantz MM, Schalken JA, Tammela TL, Visakorpi T
Eur Urol 2012 Oct;62(4):577-87. Epub 2012 Jun 5 doi: 10.1016/j.eururo.2012.05.054. PMID: 22695242

Recent clinical studies

Etiology

Radical cystectomy for bladder urothelial carcinoma with aggressive variant histology.
Mehrnoush V, Brennan L, Ismail A, Zakaria A, Elmansy H, Shahrour W, Prowse O, Kotb A
Arch Ital Urol Androl 2022 Sep 26;94(3):291-294. doi: 10.4081/aiua.2022.3.291. PMID: 36165473
Optimizing the diagnosis and management of ductal prostate cancer.
Ranasinghe W, Shapiro DD, Zhang M, Bathala T, Navone N, Thompson TC, Broom B, Aparicio A, Tu SM, Tang C, Davis JW, Pisters L, Chapin BF
Nat Rev Urol 2021 Jun;18(6):337-358. Epub 2021 Apr 6 doi: 10.1038/s41585-021-00447-3. PMID: 33824525
Neuroendocrine neoplasms of the appendix, colon and rectum.
Volante M, Grillo F, Massa F, Maletta F, Mastracci L, Campora M, Ferro J, Vanoli A, Papotti M
Pathologica 2021 Feb;113(1):19-27. doi: 10.32074/1591-951X-230. PMID: 33686307Free PMC Article
Clinical features of neuroendocrine prostate cancer.
Conteduca V, Oromendia C, Eng KW, Bareja R, Sigouros M, Molina A, Faltas BM, Sboner A, Mosquera JM, Elemento O, Nanus DM, Tagawa ST, Ballman KV, Beltran H
Eur J Cancer 2019 Nov;121:7-18. Epub 2019 Sep 13 doi: 10.1016/j.ejca.2019.08.011. PMID: 31525487Free PMC Article
The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours.
Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE
Eur Urol 2016 Jul;70(1):106-119. Epub 2016 Mar 17 doi: 10.1016/j.eururo.2016.02.028. PMID: 26996659

Diagnosis

Neuroendocrine neoplasms of the appendix, colon and rectum.
Volante M, Grillo F, Massa F, Maletta F, Mastracci L, Campora M, Ferro J, Vanoli A, Papotti M
Pathologica 2021 Feb;113(1):19-27. doi: 10.32074/1591-951X-230. PMID: 33686307Free PMC Article
Morphologic, Molecular and Clinical Features of Aggressive Variant Prostate Cancer.
Montironi R, Cimadamore A, Lopez-Beltran A, Scarpelli M, Aurilio G, Santoni M, Massari F, Cheng L
Cells 2020 Apr 25;9(5) doi: 10.3390/cells9051073. PMID: 32344931Free PMC Article
Clinicopathologic Diagnostic Approach to Aggressive Variant Prostate Cancer.
Manucha V, Henegan J
Arch Pathol Lab Med 2020 Jan;144(1):18-23. Epub 2019 Aug 12 doi: 10.5858/arpa.2019-0124-RA. PMID: 31403335
Clinical features of neuroendocrine prostate cancer.
Conteduca V, Oromendia C, Eng KW, Bareja R, Sigouros M, Molina A, Faltas BM, Sboner A, Mosquera JM, Elemento O, Nanus DM, Tagawa ST, Ballman KV, Beltran H
Eur J Cancer 2019 Nov;121:7-18. Epub 2019 Sep 13 doi: 10.1016/j.ejca.2019.08.011. PMID: 31525487Free PMC Article
Prostate Ductal Adenocarcinoma.
Amin A
Appl Immunohistochem Mol Morphol 2018 Aug;26(7):514-521. doi: 10.1097/PAI.0000000000000508. PMID: 28362706

Therapy

Current and emerging therapies for neuroendocrine prostate cancer.
Alabi BR, Liu S, Stoyanova T
Pharmacol Ther 2022 Oct;238:108255. Epub 2022 Jul 26 doi: 10.1016/j.pharmthera.2022.108255. PMID: 35905791
A phase 2 trial of avelumab in men with aggressive-variant or neuroendocrine prostate cancer.
Brown LC, Halabi S, Somarelli JA, Humeniuk M, Wu Y, Oyekunle T, Howard L, Huang J, Anand M, Davies C, Patel P, Staats J, Weinhold KJ, Harrison MR, Zhang T, George DJ, Armstrong AJ
Prostate Cancer Prostatic Dis 2022 Apr;25(4):762-769. Epub 2022 Mar 15 doi: 10.1038/s41391-022-00524-7. PMID: 35292724Free PMC Article
Prostate epithelial genes define therapy-relevant prostate cancer molecular subtype.
Han H, Lee HH, Choi K, Moon YJ, Heo JE, Ham WS, Jang WS, Rha KH, Cho NH, Giancotti FG, Choi YD
Prostate Cancer Prostatic Dis 2021 Dec;24(4):1080-1092. Epub 2021 Apr 26 doi: 10.1038/s41391-021-00364-x. PMID: 33903734Free PMC Article
Clinical and molecular features of treatment-related neuroendocrine prostate cancer.
Akamatsu S, Inoue T, Ogawa O, Gleave ME
Int J Urol 2018 Apr;25(4):345-351. Epub 2018 Feb 3 doi: 10.1111/iju.13526. PMID: 29396873
The role of genetic markers in the management of prostate cancer.
Choudhury AD, Eeles R, Freedland SJ, Isaacs WB, Pomerantz MM, Schalken JA, Tammela TL, Visakorpi T
Eur Urol 2012 Oct;62(4):577-87. Epub 2012 Jun 5 doi: 10.1016/j.eururo.2012.05.054. PMID: 22695242

Prognosis

Neuroendocrine neoplasms of the appendix, colon and rectum.
Volante M, Grillo F, Massa F, Maletta F, Mastracci L, Campora M, Ferro J, Vanoli A, Papotti M
Pathologica 2021 Feb;113(1):19-27. doi: 10.32074/1591-951X-230. PMID: 33686307Free PMC Article
Morphologic, Molecular and Clinical Features of Aggressive Variant Prostate Cancer.
Montironi R, Cimadamore A, Lopez-Beltran A, Scarpelli M, Aurilio G, Santoni M, Massari F, Cheng L
Cells 2020 Apr 25;9(5) doi: 10.3390/cells9051073. PMID: 32344931Free PMC Article
Clinical features of neuroendocrine prostate cancer.
Conteduca V, Oromendia C, Eng KW, Bareja R, Sigouros M, Molina A, Faltas BM, Sboner A, Mosquera JM, Elemento O, Nanus DM, Tagawa ST, Ballman KV, Beltran H
Eur J Cancer 2019 Nov;121:7-18. Epub 2019 Sep 13 doi: 10.1016/j.ejca.2019.08.011. PMID: 31525487Free PMC Article
EMT, stemness and tumor plasticity in aggressive variant neuroendocrine prostate cancers.
Soundararajan R, Paranjape AN, Maity S, Aparicio A, Mani SA
Biochim Biophys Acta Rev Cancer 2018 Dec;1870(2):229-238. Epub 2018 Jul 5 doi: 10.1016/j.bbcan.2018.06.006. PMID: 29981816Free PMC Article
Prostate Ductal Adenocarcinoma.
Amin A
Appl Immunohistochem Mol Morphol 2018 Aug;26(7):514-521. doi: 10.1097/PAI.0000000000000508. PMID: 28362706

Clinical prediction guides

Collecting duct carcinoma: Epidemiology, clinical characteristics and survival.
Panunzio A, Tappero S, Hohenhorst L, Cano Garcia C, Piccinelli M, Barletta F, Tian Z, Tafuri A, Briganti A, De Cobelli O, Chun FKH, Tilki D, Terrone C, Kapoor A, Saad F, Shariat SF, Cerruto MA, Antonelli A, Karakiewicz PI
Urol Oncol 2023 Feb;41(2):110.e7-110.e14. Epub 2022 Nov 28 doi: 10.1016/j.urolonc.2022.11.009. PMID: 36456452
High-grade prostatic intraepithelial neoplasia, PIN-like carcinoma, ductal carcinoma, and intraductal carcinoma of the prostate.
Zhou M
Mod Pathol 2018 Jan;31(S1):S71-79. doi: 10.1038/modpathol.2017.138. PMID: 29297491
The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours.
Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE
Eur Urol 2016 Jul;70(1):106-119. Epub 2016 Mar 17 doi: 10.1016/j.eururo.2016.02.028. PMID: 26996659
Aggressive variants of castration-resistant prostate cancer.
Beltran H, Tomlins S, Aparicio A, Arora V, Rickman D, Ayala G, Huang J, True L, Gleave ME, Soule H, Logothetis C, Rubin MA
Clin Cancer Res 2014 Jun 1;20(11):2846-50. Epub 2014 Apr 11 doi: 10.1158/1078-0432.CCR-13-3309. PMID: 24727321Free PMC Article
Recent developments in vulvovaginal pathology.
McCluggage WG
Histopathology 2009 Jan;54(2):156-73. doi: 10.1111/j.1365-2559.2008.03098.x. PMID: 18637148

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...